Pasar al contenido principal

ESTRES Y ALCOHOL COMO FACTORES DE RIESGO PSIQUIATRICO Y CARDIOVASCULAR ASOCIADOS A INFLAMACION: EVALUACION ANTIINFLAMATORIA DEL SISTEMA QUIMIOQUINA CX3CL1/CX3CR1

PI19/00886

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD (FIMABIS)
Centro realización INSTITUTO DE INVESTIGACION BIOMEDICA DE MALAGA (IBIMA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dysregulation of Plasma Growth Factors and Chemokines in Cocaine Use Disorder, Implications for Dual Diagnosis with Schizophrenia and Antisocial Personality Disorder in an Exploratory Study

  • Torres-Galván, Sandra
  • Flores-López, María|||0000-0003-3489-1465
  • Ochoa, Enrique
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Araos, Pedro|||0000-0001-5172-8796
  • Herrera-Imbroda, Jesús
  • Muga, Roberto|||0000-0001-6301-431X
  • Serrano, Antonia
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
  • Haro, Gonzalo
  • García Marchena, Nuria|||0000-0002-0575-3613
Dual diagnosis in individuals with cocaine use disorders (CUDs) presents a mental health challenge marked by an increased susceptibility to disabling morbidities and premature mortality. Despite extensive research on depression and anxiety, other prevalent comorbidities, such as psychotic and personality disorders, have received less attention. This study explores inflammation-related mediators as potential biomarkers for CUD and dual diagnosis with schizophrenia (SCZ) or antisocial personality disorder (APD). This exploratory study included 95 participants, comprising 40 healthy subjects and 55 abstinent patients with CUD. Lifetime CUD was diagnosed either as single diagnosis (CUD group, N = 25) or as a dual diagnosis (DD group. N = 30) with SCZ (CUD+SCZ subgroup) or APD (CUD+APD subgroup). Participants were clinically assessed, and the plasma concentrations of growth factors (i.e., G-CSF, BDNF, and VEGF-A) and chemokines (i.e., CCL11/eotaxin-1, CCL2/MCP-1, and CXCL12/SDF-1) were determined and log(10)-transformed for analysis. Growth factors and chemokines were dysregulated by CUD and psychiatric diagnoses. Specifically, patients in the CUD group exhibited significantly lower concentrations of G-CSF and CCL11/eotaxin-1 than the control group. In contrast, the DD group showed significantly higher concentrations of all analytes than both the CUD and control groups. Additionally, no differences in these analytes were observed between the CUD+SCZ and CUD+APD subgroups within the DD group. Regarding cocaine-related variables, significant associations were identified in the CUD group: an inverse correlation between the age at first cocaine use and the concentrations of BDNF and CCL2/MCP-1; and a positive correlation between the duration of the cocaine abstinence and the concentrations of BDNF and CCL11/eotaxin-1. Lastly, a logistic regression model incorporating all these analytes demonstrated high discriminatory power in distinguishing patients with CUD alone from those with dual diagnosis. Individuals with dual diagnosis of CUD exhibit elevated concentrations of growth factors and chemokines, distinguishing them from those with CUD alone. It is unclear whether the differences in these inflammatory mediators are specific to the presence of SCZ and APD. The study highlights potential biomarkers and associations, providing valuable insights into the intricate interplay of CUD and psychiatric disorders to enhance clinical diagnosis and therapeutics.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder

  • Galván, Sandra Torres
  • Flores-López, María|||0000-0003-3489-1465
  • Romero-Sanchiz, Pablo
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Porras-Perales, Oscar
  • Nogueira-Arjona, Raquel
  • Mayoral-Cleries, Fermín
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Muga, Roberto|||0000-0001-6301-431X
  • Pavón, Francisco Javier
  • García Marchena, Nuria|||0000-0002-0575-3613
  • de Fonseca, Fernando Rodríguez
Granulocyte colony-stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = - 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls (p < 0.05), specifically in the cocaine subgroup (p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls (p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Flores-López, María|||0000-0003-3489-1465
  • Papaseit, Esther|||0000-0003-2620-4274
  • García Marchena, Nuria|||0000-0002-0575-3613
  • Ruiz, Juan Jesús
  • Ortega-Pinazo, Jesús
  • Serrano, Antonia
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Suarez, Juan|||0000-0001-5254-9802
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Araos, Pedro|||0000-0001-5172-8796
(1) Background: Alcohol Use Disorder (AUD) is associated with functional disruption of several brain structures that may trigger cognitive dysfunction. One of the mechanisms of alcohol-associated cognitive impairment has been proposed to arise from its direct impact on the immune system, which culminates in the release of cytokines and chemokines which can eventually reach the brain. Alcohol can also disrupt the blood-brain barrier, facilitating the penetration of pro-inflammatory molecules throughout vascular endothelial growth factor A (VEGFA). Thus, alcohol-induced alterations in chemokines and VEGFA might contribute to the neuroinflammation and cognitive impairment associated with AUD. (2) Methods: The present cross-sectional study investigates whether patients with AUD (n = 86) present cognitive disability associated to alterations in plasma concentration of SDF-1, fractalkine, eotaxin, MCP-1, MIP-1α and VEGFA when compared to control subjects (n = 51). (3) Results: The analysis indicated that SDF-1 and MCP-1 concentrations were higher in AUD patients than in controls. Concentrations of VEGFA were higher in AUD patients with severe frontal deficits, and the score of frontal lobe functions was negatively correlated with VEGFA and fractalkine. Acute alcohol effects on VEGFA plasma levels in healthy volunteers demonstrated the induction of VEGFA release by heavy alcohol drinking. VEGFA was positively correlated with pro-inflammatory chemokines in AUD patients with frontal cognitive impairment. (4) Conclusions: we propose VEGFA/chemokine monitoring as biomarkers of potential cognitive impairment in AUD patients.